uploads/2018/06/capsule-1079838_1280-1.jpg

What’s the Upside Potential of Nektar Therapeutics?

By

Updated

Company overview

Nektar Therapeutics (NKTR) is a San-Francisco-headquartered biopharmaceutical company with a focus on research. It is developing drug candidates that make use of Nektar’s advanced polymer conjugate technology platforms. These platforms are designed to enable the development of new molecular entities that target known mechanisms of action. These investigational drugs are aimed at treating cancer, autoimmune disease, and chronic pain.

Analyst recommendations

Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating, while one analyst has given it a “hold” rating. The mean rating for the stock is 1.8 with a target price of $101.56, implying an upside of 81.5% over the stock’s closing price of $55.96 on June 5.

Peer ratings

In June 2018, six of the total 12 analysts covering Ironwood Pharmaceuticals (IRWD) have given the stock a “buy” or a higher rating. Four analysts have given Ironwood Pharmaceuticals a “hold” rating, while two analysts have given it a “sell” rating. The mean rating for the stock is 2.5 with a target price of $19.5.

Two of the five analysts covering Progenics Pharmaceuticals (PGNX) in June 2018 have given the stock a “buy” rating, while three analysts have given it a “strong buy” rating. The mean rating for the stock is 1.4 with a target price of $14.2. In June 2018, five of the total 11 analysts covering Alkermes (ALKS) have given it a “buy” or a higher rating, while six analysts have given the stock a “hold” rating. The mean rating for the stock is 2.4 with a target price of $55.18.

In the next part of the series, we’ll take a look at the preliminary data from NKTR-214 and Opdivo combination and the subsequent effect on Nektar Therapeutics’ stock price.

More From Market Realist